N-glycosylation Customization of Rituximab using FastPharming™ system

Roman Subbotin, Sreenath Palle, Jasmine Deng, Zhongjie Ren, Yo Ng, Phyllis Loupov, Vally Kommireni, Brian Berquist and Sylvain Marcel*  
iBio CDMO, LLC, 8800 Health Science Center Parkway, Bryan, TX 77807, USA  
*Correspondence: smarcel@ibio.com

ABSTRACT

N-glycosylation is known to affect the biological activity of human therapeutics such as anti-cancer monoclonal antibodies, blood factors, or lysosomal enzymes. Over the last decade, several methods have been developed to enable the engineering of N-glycosylation profiles present on certain drugs. For instance, Chinese Hamster Ovary (CHO) cells or the yeast Pichia pastoris have been modified to produce afucosylated antibodies to enhance the Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) of the drug candidates. However, the availability of such cell lines for development or commercial purposes remains limited or expensive. iBio’s FastPharming™ technology uses a protein expression platform that combines the transfection of Nicotiana benthamiana plants at pilot and commercial scales and a unique set of glycan engineering techniques. Using rituximab as a model protein, we demonstrated the power of glycosylation engineering by designing that FastPharming offers.

We first generated 40 rituximab using a transgenic plant engineered to remove core fucose. With a second transgenic plant expressing the human Fc-galactosyltransferase, G1 and 42 rituximab glycoforms were produced. Finally, we modified our plant transfection method to introduce the manniosidase I inhibitor kifunensine to generate rituximab decorated with oligomannose residues. All glyco-engineered rituximab proteins show enhanced ADCC activity in vitro without affecting the protein ability to bind CD-20 receptor.

Rituximab Expression using FastPharming Technology

**Rituximab expression process in Nicotiana benthamiana**

| 01. The Gene of Interest (GOI) is inserted into iBio’s proprietary plant expression vectors |
| 02. Plants are grown hydroponically using chemically defined nutrients in vertical farming rooms |
| 03. Plant expression vectors are mobilized into Agrobacterium tumefaciens and amplified in bioreactors |
| 04. GOI is transferred to plant cells during a transfection process designed for manufacturing scale |
| 05. Protein of interest is expressed transiently in plants for 6-8 days before being harvested for purification |
| 06. Cleared plant protein extract enters the downstream process train in classified clean rooms for product purification and vialing |

**Table 1.** Rituximab expression in different plants or plant treatments.

<table>
<thead>
<tr>
<th>Plant line</th>
<th>ΔXT/FT</th>
<th>ΔXT/FT + GaIT</th>
<th>Treated with kifunensine</th>
<th>Wild type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expected Major Protein Glycogram</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expression</td>
<td>mg/kg biomass</td>
<td>351 ± 25</td>
<td>375 ± 32</td>
<td>285 ± 51</td>
</tr>
</tbody>
</table>

**Figure 2.** SDS-PAGE (reduced) of purified rituximab (RTX) produced in ΔXT/FT and ΔXT/FT+GaIT lines.

**Material and Methods**

**Material**

Seeds of Nicotiana benthamiana wild type, C105 ΔXT/FT and C105-GaIT transgenic lines were grown hydroponically under LED lights at the iBio manufacturing facility, Bryan, Texas. The rituximab sequence was obtained from DrugBank (Accession DB00073).

**Methods**

**Cloning and Protein Expression:** Rituximab heavy and light chain genes were cloned into iBio proprietary plant expression vectors and mobilized into Agrobacterium tumefaciens GV3101:pMP90 and transferred to 4-week-old N. benthamiana plants by Agroinfiltration as described in Kommireni et al., 2019. For Kifunensine treatments, concentration of 5µM, 2.5µM, 1.25µM, 0.75µM, 0.375µM and 0.25µM were used in the infiltration solution.

**Protein Purification:** Infiltrated leaves were harvested at 6 or 7dpi and total soluble proteins were extracted in 50mM sodium phosphate buffer pH 8, 10% DTT, 60mM ascorbic acid. Rituximab was capture by protein A chromatography as described in Bennett et al., 2018. Elution fractions were analyzed on a 4-12% Bis-Tris gradient NuPAGE™ gel under reducing and non-reducing conditions and stained using the GenScript eStain™ L1 Protein Staining System.

**Glycopeptide Analysis by LC-MS:** Sample preparation was performed using standard procedure for proteomic sample preparation. All samples were reduced with DTT, alkylated with iodoacetamide and were subjected to trypsin proteolysis. Resulting peptide mixtures were desalted using in-house prepared C18 SPE and were subjected to LC-MS/MS analysis. Peptides were separated using 15min 5 to 95% acetonitrile gradient on C18 column at 40°C. Eluted peptides were ionized at the Turbo V source (SCIEX) at 5kV and were analyzed using SCIEX 5600 TripleTOF instrument. Standard top 20 IA experiment was performed for protein identification. Glycopeptide ions were identified using 204 Th diagnostic MS2 fragment peak and by matching MS1 ion masses to theoretical rituximab glycopeptide masses.

**Binding and Cell-Based Assay:** Rituximab binding to target cells W2-2S was determined by flow cytometry as described in Kommireni et al., 2019. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) assay was performed using the Promega ADCC Reporter Bioassay with W2-2S cells and FcγRIIIa receptor, TV16 variant effector cells. GraphPad prism software was used to plot normalized Relative Luminescence Units (RLU) against rituximab concentration in Log10 form. The half maximal Effective Concentrations (EC50) were calculated from non-linear regression curves.

**ADCC activity and CD-20 binding of customized rituximab**

**Figure 4.** In vitro ADCC activity of different rituximab glycoforms compared to rituximab standard.

○ Superior ADCC was confirmed with all afucosylated rituximab proteins

○ Rituximab glycosylation profiles did not affect CD-20 binding efficiency

**Figure 5.** Rituximab binding affinities to CD-20 receptor on Wi2-S target cells analyzed by flow cytometry. Peaks on the left represent mlgG2a isotype control while peaks on the right represent binding of rituximab samples.